Supplementary material 5. Meta-analysis results of adverse drug reactions (Figures S25-34)

Aidi inje	ction	Gemcitabine and o	isplatin		Odds Ratio	Odds Ratio	Risk of Bias
Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl	ABCDEFG
5	19	8	19	2.9%	0.49 [0.13, 1.93]		?????
12	45	8	45	2.9%	1.68 [0.61, 4.62]		+ ? ? ? + +
9	29	17	23	6.4%	0.16 [0.05, 0.54]		?????++++
11	34	23	34	7.6%	0.23 [0.08, 0.63]		????? 🗣 🛑 🗣
25	70	31	70	9.8%	0.70 [0.35, 1.38]		🕀 ? ? ? 🕀 🛑 🖶
16	30	21	30	4.8%	0.49 [0.17, 1.41]		?????
10	36	21	36	7.4%			?????
3	32	11	32	4.9%			????+++
16	30	24	30	5.5%			?????
							?????
7							?????
4							?????+++
2							+ ? ? ? + + +
							• ? ? ? • • •
						← .	?????
						_	????
30	42	34	39	4.9%	0.37 [0.12, 1.16]		?????
	642		632	100.0%	0.36 [0.28, 0.47]	◆	
218		342					
23.27, df =	16 (P =	0.11); l ² = 31%					
							100
	Events 5 12 9 11 255 16 10 3 3 16 16 16 16 16 7 4 2 23 12 30 30 218 23.27, df =	5 19 12 45 9 29 91 34 25 70 16 30 16 30 16 30 16 28 7 30 12 44 2 40 17 45 23 33 12 58 30 42 248 218 23.27, df = 16 (P =	Events Total Events 5 19 8 12 45 8 9 29 17 11 34 23 25 70 31 16 30 21 10 36 21 13 32 111 16 30 24 16 28 23 7 30 12 4 41 13 2 40 3 17 45 26 23 33 33 12 58 34 30 42 34	Events Total Events Total 5 19 8 19 12 45 8 45 9 29 17 23 11 34 23 34 25 70 31 70 16 30 21 30 10 36 21 30 16 30 24 30 16 28 23 28 7 30 12 30 4 41 13 41 2 40 3 39 17 45 26 45 30 42 34 39 642 632 232 632 213 58 34 58 30 42 34 39 642 632 232 237, df = 16 (P = 0.11); P = 31%	Events Total Events Total Weight 5 19 8 19 2.9% 12 45 8 45 2.9% 9 29 17 23 6.4% 11 34 23 34 7.6% 16 30 21 30 4.8% 10 36 2.1 30 4.8% 10 36 2.1 36 7.4% 16 30 2.1 36 7.4% 16 30 2.1 32 4.9% 16 2.8 2.3 2.8 4.8% 7 30 12 30 4.5% 4 41 13 41 5.8% 12 58 34 58 13.2% 30 4.2 34 39 4.9% 642 642 632 100.0% 23.37, df = 16 (P = 0.11); P = 31% 542 342	Events Total Events Total Weight M-H. Fixed. 95% CI 5 19 8 19 2.9% 0.49 [0.13, 1.93] 12 45 8 45 2.9% 1.68 [0.61, 4.62] 9 29 17 23 6.4% 0.16 [0.05, 0.54] 11 34 23 34 7.6% 0.23 [0.08, 0.63] 25 70 31 70 9.8% 0.70 [0.05, 1.38] 16 30 21 30 4.8% 0.49 [0.17, 1.41] 10 36 21 36 7.4% 0.27 [0.10, 0.74] 3 32 11 32 4.9% 0.20 [0.05, 0.80] 16 30 24 30 5.5% 0.29 [0.09, 0.90] 16 30 24 30 5.5% 0.29 [0.09, 0.90] 7 30 12 30 4.5% 0.29 [0.00, 0.90] 7 30 12 30 30 1.4% 0.63 [0.10, 4.00] </td <td>Events Total Events Total Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl 5 19 8 19 2.9% 0.49 [0.13, 1.83] </td>	Events Total Events Total Weight M-H, Fixed, 95% Cl M-H, Fixed, 95% Cl 5 19 8 19 2.9% 0.49 [0.13, 1.83]

 Risk of bias legend

 (A) Random sequence generation (selection bias)
 (B) Allocation concealment (selection bias)

 (C) Blinding of participants and personnel (performance bias)
 (D) Blinding of outcome assessment (detection bias)

 (E) normplete outcome data (attrition bias)
 (F) Selective reporting (reporting bias)

 (G) Other bias
 (F) Selective reporting (reporting bias)

Figure S25 The analysis of myelosuppression between the two groups

	Aidi inje	ction	Gemcitabine and	cisplatin		Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events		Weight	M-H, Fixed, 95% CI Year	M-H, Fixed, 95% Cl	ABCDEFG
Feng,X.2008	64	68	60	62	0.9%	0.53 [0.09, 3.02] 2008		????? 🗣 🖷 🖶
Wang,Y.2009	26	32	22	27	1.0%	0.98 [0.26, 3.67] 2009		?????
Wen,K.2009	23	38	31	38	2.8%	0.35 [0.12, 0.99] 2009		?????+++
Zhang, L.2009	5	32	14	31	2.8%	0.22 [0.07, 0.74] 2009		????? 🗣 🖶 🖶
Hong,Y.2010	26	90	31	70	5.7%	0.51 [0.27, 0.98] 2010		?????
Hou,A.2010	14	40	22	38	3.4%	0.39 [0.16, 0.98] 2010		?????
Lu.Z.2011	11	34	20	34	3.1%	0.33 [0.12, 0.90] 2011		????
Zhang,Y. 2012	12	41	17	42	2.7%	0.61 [0.24, 1.52] 2012		????
Xu,Y.2012	23	33	33	33	2.4%	0.03 [0.00, 0.60] 2012		????
Fu, L.2012	23	35	32	35	2.3%	0.20 [0.05, 0.81] 2012		
Wang, J.2012	7	25	9	24	1.5%	0.65 [0.19, 2.16] 2012		2 2 2 2 4 4 4
Wang,Y.2012	19	36	26	36	2.8%	0.43 [0.16, 1.15] 2012		2 2 2 2 4 4 4
Sun,J.2012	23	30	30	30	2.8%			
	13	34	22		3.2%	0.28 [0.08, 0.99] 2012		2 2 2 2 4
Ku, H.2013	34	38 49	47	42	3.2%	0.47 [0.19, 1.17] 2013		2 2 2 2 4 4 4
Cheng, B.2014	34 27			52		0.24 [0.08, 0.73] 2014		
.iu,Y.2014		43	36	43	3.1%	0.33 [0.12, 0.91] 2014		2 2 2 2 4
.i, J.2014	5	27	6	27	1.1%	0.80 [0.21, 3.00] 2014		
.i, X.2015	2	20	8	20	1.7%	0.17 [0.03, 0.92] 2015		2 2 2 2 4 4 4
hao, S.2015	7	43	10	43	1.9%	0.64 [0.22, 1.88] 2015		
hang, M.2015	26	39	28	32	2.4%	0.29 [0.08, 0.99] 2015		
ling, S.2015	16	31	16	31	1.8%	1.00 [0.37, 2.71] 2015		
Zhu, H.2015	6	21	15	21	2.5%	0.16 [0.04, 0.61] 2015		
lan, R.2015	7	36	11	36	2.0%	0.55 [0.18, 1.63] 2015		
.i, Jc.2016	14	35	26	35	3.6%	0.23 [0.08, 0.64] 2016		????+
/la, Y. 2016	7	33	15	35	2.7%	0.36 [0.12, 1.05] 2016		????+++
ang, L.2016	5	45	13	45	2.7%	0.31 [0.10, 0.95] 2016		????
.i, J.2016	12	47	19	47	3.3%	0.51 [0.21, 1.21] 2016		?????
Zhang, S.2016	2	19	4	19	0.8%	0.44 [0.07, 2.76] 2016		?????
Zhang, H.2017	13	52	22	52	3.8%	0.45 [0.20, 1.05] 2017		• ? ? ? • • •
Ma, M.2017	11	42	16	42	2.7%	0.58 [0.23, 1.46] 2017		• ? ? ? • • •
luang, W.2017	10	39	12	40	2.0%	0.80 [0.30, 2.16] 2017		🙂 ???? 🕀 🖶 🖶
Su, S.2017	2	40	2	39	0.4%	0.97 [0.13, 7.28] 2017		🕒 ? ? ? 🕀 🖶 🕀
Vu, Y.2017	3	109	9	109	2.0%	0.31 [0.08, 1.19] 2017		•••??
Vu, T.2017	10	67	21	68	4.1%	0.39 [0.17, 0.92] 2017		?????
hang, H.2018	13	30	22	30	2.9%	0.28 [0.09, 0.82] 2018		🕒 ? ? ? 🕀 🛑 🖶
hou, D.2018	11	58	13	58	2.4%	0.81 [0.33, 1.99] 2018		<mark>? ? ? ? 🕀 🖶</mark>
Guo, X.2020	7	51	16	51	3.2%	0.35 [0.13, 0.94] 2020		• ? ? ? • • •
Tan. H.2020	51	60	57	60	2.0%	0.30 [0.08, 1.16] 2020		• ? ? ? + + +
Chen.C.2020	33	49	43	49	3.2%	0.29 [0.10, 0.82] 2020		?????
Ku,Z.2020	2	40	6	40	1.3%	0.30 [0.06, 1.58] 2020	—— — —————————————————————————————————	• ? ? ? • • •
	-		-				•	
Fotal (95% CI)	e e -	1701		1670	100.0%	0.41 [0.35, 0.49]	▼	
Total events	626		862					
Heterogeneity: Chi ² =							0.001 0.1 1 10	1000
Test for overall effect:	Z = 10.32 (P < 0.00	0001)				Favours[Aidi injection] Favours[Gemcitabir	

 Risk of bias legend

 (A) Random sequence generation (selection bias)
 (B) Allocation concealment (selection bias)

 (C) Blinding of participants and personnel (performance bias)
 (D) Blinding of outcome assessment (detection bias)

 (E) Incomplete outcome data (attrition bias)
 (F) Selective reporting (reporting bias)

 (G) Other bias
 (F) Selective reporting (reporting bias)

Figure S26 The analysis of neutropenia between the two groups

	Aidi inje	ction	Gemcitabine and ci	splatin		Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI Ye	ar M-H, Fixed, 95% Cl	ABCDEFG
Feng,X.2008	62	68	62	62	2.4%	0.08 [0.00, 1.39] 20		????? 🔁 🛑 🖶
Zhang, L.2009	4	32	9	31	3.2%	0.35 [0.09, 1.29] 20	9	????? 🔁 🛑 🖶
Wang,Y.2009	4	32	2	27	0.8%	1.79 [0.30, 10.60] 20		?????
Wen,K.2009	22	38	24	38	4.0%	0.80 [0.32, 2.02] 20		?????++++
Hou.A.2010	3	40	8	38	3.0%	0.30 [0.07, 1.25] 20		????? 🔁 🛑 🖶
Hong,Y.2010	12	90	23	70	8.9%	0.31 [0.14, 0.69] 20	0	?????++++
Wang, Y.2012	7	36	15	36	4.8%	0.34 [0.12, 0.97] 20		?????+++
Wang, J.2012	4	25	7	24	2.4%	0.46 [0.12, 1.85] 20		?????+++
Xu,Y.2012	14	33	24	33	5.5%	0.28 [0.10, 0.77] 20		????? 🔁 🛑 🖶
Zhang,Y. 2012	6	41	11	42	3.7%	0.48 [0.16, 1.46] 20		????? 🕀 🕀 🖶
Xu, H.2013	4	38	10	42	3.4%	0.38 [0.11, 1.32] 20		????? 🔁 🛑 🖶
Cheng, B.2014	9	49	14	52	4.4%	0.61 [0.24, 1.58] 20		?????++++
Li, J.2014	3	27	2	27	0.7%	1.56 [0.24, 10.19] 20		????? 🔁 🛑 🖶
Liu,Y.2014	26	43	28	43	4.4%	0.82 [0.34, 1.97] 20		🕀 ? ? ? 🖶 🖶 🖶
Han, R.2015	2	36	4	36	1.5%	0.47 [0.08, 2.75] 20		+ ? ? ? + +
Zhu, H.2015	5	21	15	21	4.5%	0.13 [0.03, 0.50] 20		????? 🔁 🖶 🖶
Zhao, S.2015	2	43	4	43	1.5%	0.48 [0.08, 2.75] 20		?????
Ning, S.2015	7	31	9	31	2.8%	0.71 [0.23, 2.24] 20		• ? ? ? • • •
Fang, L.2016	7	45	15	45	5.0%	0.37 [0.13, 1.02] 20		?????
Ma, Y. 2016	4	33	11	35	3.7%	0.30 [0.08, 1.07] 20		?????+++
Li, J.2016	6	47	10	47	3.5%	0.54 [0.18, 1.64] 20		????? 🔁 🛑 🖶
Huang, W.2017	5	39	7	40	2.4%	0.69 [0.20, 2.40] 20		🕒 ? ? ? 🖶 🛑 🖶
Su, S.2017	1	40	2	39	0.8%	0.47 [0.04, 5.45] 20		+ ? ? ? + +
Zhou, D.2018	16	58	20	58	5.7%	0.72 [0.33, 1.60] 20		????? 🔁 🖶 🖶
Geng,K.2020	12	45	10	45	2.9%	1.27 [0.49, 3.34] 203		+ ? ? ? + + +
Guo, X.2020	4	51	12	51	4.4%	0.28 [0.08, 0.93] 202		+ ? ? ? + + +
Tan, H.2020	34	60	46	60	7.9%	0.40 [0.18, 0.87] 203		🛨 ? ? ? 🖶 🖶
Xu,Z.2020	1	40	5	40	1.9%	0.18 [0.02, 1.61] 20		🔁 ? ? ? 🖶 🖶 🕀
Total (95% CI)		1181		1156	100.0%	0.48 [0.39, 0.59]	•	
Total events	286		409					
Heterogeneity: Chi ² = 2		27 (P =					+ + + +	
Test for overall effect:							0.001 0.1 1 10	1000
	L 0.00 (i	. 0.000	,				Favours[Aidi injection] Favours[Gemcitabi	ne and cisplatin]
Risk of bias legend								
(A) Random sequence	generation	n (select	ion bias)					
(B) Allocation conceal	ment (selec	tion bia	s)					
(C) Blinding of participa	ants and pe	ersonnel	(performance bias)					
(D) Blinding of outcom	e assessm	ent (dete	ection bias)					
(E) Incomplete outcom	e data (atti	rition bia	s)					
(F) Selective reporting								
(G) Other bias		,						

Figure S27 The analysis of thrombocytopenia between the two groups

	Aidi inje	ction	Gemcitabine and c	isplatin		Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI Year	M-H, Fixed, 95% Cl	ABCDEFG
Wang,Y.2009	5	32	5	27	4.5%	0.81 [0.21, 3.18] 2009		?????
Cheng, B.2014	44	49	43	52	4.2%	1.84 [0.57, 5.94] 2014		?????
_i, J.2014	1	27	4	27	3.8%	0.22 [0.02, 2.12] 2014		????? 🗣 🛑 🖲
i, X.2015	15	20	16	20	3.9%	0.75 [0.17, 3.33] 2015		• ? ? ? • • •
hao, S.2015	0	43	1	43	1.5%	0.33 [0.01, 8.22] 2015		?????+++
i, Jc.2016	7	35	16	35	12.6%	0.30 [0.10, 0.86] 2016		?????
Ma, M.2017	10	42	14	42	10.5%	0.63 [0.24, 1.63] 2017		🖶 ? ? ? 🖶 🛑 🤂
Nu, T.2017	6	67	15	68	13.3%	0.35 [0.13, 0.96] 2017		<u>????</u> €€€
Nu, Y.2017	20	109	23	109	18.5%	0.84 [0.43, 1.64] 2017		• • ? ? • • •
Zhang, H.2018	7	40	15	40	12.2%	0.35 [0.13, 1.00] 2018		🖶 ? ? ? 🖶 🛑 🤂
Tan, H.2020	41	60	48	60	15.0%	0.54 [0.23, 1.24] 2020		🕀 ? ? ? 🖶 🖶 🖷
otal (95% CI)		524		523	100.0%	0.59 [0.43, 0.80]	•	
Total events	156		200					
leterogeneity: Chi ² = !	9.52, df = 1	0 (P = 0	.48); I ² = 0%					
est for overall effect:	Z = 3.32 (P	9 = 0.000	09)				0.005 0.1 1 10 Favours[Aidi injection] Favours[Gemcitabi	200 ne and cisplatin]
Risk of bias legend								
A) Random sequence	generation	n (select	ion bias)					
B) Allocation concealing								

(B) Allocation concealment (selection bias)
 (C) Blinding of participants and personnel (performance bias)
 (D) Blinding of outcome assessment (detection bias)
 (E) Incomplete outcome data (attrition bias)
 (F) Selective reporting (reporting bias)
 (G) Other bias

Figure S28 The analysis of anemia between the two groups

tudy or Subgroup	Aidi inje Events	Total	Gemcitabine and o Events		Weight	Odds Ratio M-H, Fixed, 95% CI Year	Odds Ratio M-H. Fixed, 95% Cl	Risk of Bias
ou,Y.2006	32	42	29	39	1.2%	1.10 [0.40, 3.03] 2006		????
eng,X.2008	55	68	29 54	62	1.2%	0.63 [0.24, 1.63] 2008		2 2 2 2 4
ong,Z.2009	10	30	54 11	30	1.9%	0.86 [0.30, 2.50] 2009		2 2 2 2 4
Vang,Y.2009	5	30	5	27	0.8%	0.86 [0.30, 2.50] 2009		2 2 2 2 4 4
vang, 1.2009 .v,D.2009	10	30	19	30	2.2%	0.29 [0.10, 0.84] 2009		2 2 2 2 4
				30				????
Ven,K.2009	20	38	29		2.4%	0.34 [0.13, 0.92] 2009		2 2 2 2 4
hang, L.2009	11	32	20	31	2.3%	0.29 [0.10, 0.81] 2009		2 2 2 2 4
lou,A.2010	5	40	12	38	1.8%	0.31 [0.10, 0.99] 2010		2 2 2 2 4
i,Z.2010	16	36	20	36	1.9%	0.64 [0.25, 1.62] 2010		2 2 2 2 4
.iu,Y.2010	7	32	14	32	1.9%	0.36 [0.12, 1.07] 2010		????
long,Y.2010	20	90	29	70	4.4%	0.40 [0.20, 0.80] 2010		2 2 2 2 4
Shi,X.2010	12	28	20	28	2.0%	0.30 [0.10, 0.91] 2010		
.u,Z.2011	10	34	19	34	2.3%	0.33 [0.12, 0.90] 2011		????+
le,W.2011	12	29	13	23	1.5%	0.54 [0.18, 1.64] 2011		????
Sun,J.2012	28	34	29	34	0.9%	0.80 [0.22, 2.94] 2012		
Vang,Y.2012	21	36	28	36	2.0%	0.40 [0.14, 1.12] 2012		????
(u,Y.2012	7	33	18	33	2.4%	0.22 [0.08, 0.66] 2012		????
Vang,J.2012	5	25	8	24	1.1%	0.50 [0.14, 1.83] 2012		???? €€
hang,Y. 2012	9	41	14	42	1.9%	0.56 [0.21, 1.50] 2012		????++
Cai,H.2013	6	19	8	19	0.9%	0.63 [0.17, 2.40] 2013		?????
(u, H.2013	20	38	30	42	2.3%	0.44 [0.18, 1.12] 2013		?????
u,S.2013	13	34	14	34	1.5%	0.88 [0.33, 2.34] 2013		?????
ai,L.2013	20	70	28	70	3.4%	0.60 [0.30, 1.21] 2013		• ? ? ? • 🖝
i, H.2014	18	30	22	30	1.5%	0.55 [0.18, 1.62] 2014		?????
cheng, B.2014	7	49	7	52	1.0%	1.07 [0.35, 3.31] 2014		????++
Ven, H.2014	23	45	39	45	3.3%	0.16 [0.06, 0.45] 2014		+ ? ? ? + + (
iu.Y.2014	24	43	32	43	2.4%	0.43 [0.17, 1.08] 2014		+ ? ? ? + +
ling, S.2015	12	31	16	31	1.7%	0.59 [0.22, 1.62] 2015		€??? €€
i, X.2015	15	20	15	20	0.6%	1.00 [0.24, 4.18] 2015		+ ? ? ? + +
hu, H.2015	7	21	16	21	1.8%	0.16 [0.04, 0.60] 2015		?????
hao, S.2015	5	43	10	43	1.5%	0.43 [0.13, 1.40] 2015		????
hang, M.2015	32	39	27	32	0.9%	0.85 [0.24, 2.97] 2015		
hang, S.2016	2	19	3	19	0.5%	0.63 [0.09, 4.26] 2016		????
ang, L.2016	6	45	14	45	2.1%	0.34 [0.12, 0.99] 2016		????
i, J.2016	15	47	27	47	3.2%	0.35 [0.15, 0.81] 2016		????
/a, Y. 2016	5	33	13	35	1.8%	0.30 [0.09, 0.98] 2016		????
i, Jc.2016	7	35	19	35	2.6%	0.21 [0.07, 0.61] 2016		????
Su, S.2017	4	40	3	39	0.5%	1.33 [0.28, 6.39] 2017		
hang, H.2017	16	52	29	52	3.4%	0.35 [0.16, 0.79] 2017		
Vu, Y.2017	37	109	63	109	7.1%	0.38 [0.22, 0.65] 2017		
Vu, T.2017 Vu, T.2017	11	67	23	68	3.3%	0.38 [0.22, 0.85] 2017		? ??? ++
hang, H.2018	7	40	18	40	2.5%	0.26 [0.09, 0.72] 2018		
hou, D.2018	29	40 58	31	40 58	2.5%	0.87 [0.42, 1.81] 2018		? ? ? ? .
iu,D.2019	29	56 41	15	41	2.7%			2222
	21	41	30	41	2.3%	0.24 [0.08, 0.75] 2019		
Geng,K.2020 Guo, X.2020	21		30	45 51		0.44 [0.19, 1.03] 2020		
		51		51 60	2.0%	0.32 [0.10, 0.97] 2020		
an, H.2020	47	60	54		2.0%	0.40 [0.14, 1.14] 2020		????
Chen,C.2020 (u,Z.2020	40 2	49 40	42 7	49 40	1.3% 1.1%	0.74 [0.25, 2.18] 2020 0.25 [0.05, 1.28] 2020		
	-						•	
otal (95% CI)	750	2043	1050	2002	100.0%	0.45 [0.39, 0.51]	•	
otal events	756		1059					
leterogeneity: Chi ² =							0.02 0.1 1 10	50
		P < 0.00	0001)				Favours[Aidi injection] Favours[Gemcitabir	

 Risk of bias legend

 (A) Random sequence generation (selection bias)

 (B) Allocation concealment (selection bias)

 (C) Blinding of participants and personnel (performance bias)

 (D) Blinding of outcome assessment (detection bias)

 (E) Incomplete outcome data (attrition bias)

 (F) Selective reporting (reporting bias)

 (G) Other bias

Figure S29 The analysis of gastrointestinal toxicity between the two groups

	Aidi inje		Gemcitabine and			Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events		Weight	M-H, Fixed, 95% CI Yea		
Wen,K.2009	4	38	6	38	2.3%	0.63 [0.16, 2.43] 200		
Wang,Y.2009	2	32	1	27	0.4%	1.73 [0.15, 20.23] 200		
Hou,A.2010	1	40	1	38	0.4%	0.95 [0.06, 15.73] 201		
Hong,Y.2010	8	90	12	70	5.3%	0.47 [0.18, 1.23] 201		
Wang, J.2012	5	25	5	24	1.8%	0.95 [0.24, 3.81] 201		
Sun,J.2012	6	34	7	34	2.5%	0.83 [0.25, 2.78] 201		
Wang,Y.2012	5	36	7	36	2.6%	0.67 [0.19, 2.34] 201		
Zhang,Y. 2012	8	41	9	42	3.1%	0.89 [0.31, 2.59] 201		~~~~
Cheng, B.2014	8	49	12	52	4.2%	0.65 [0.24, 1.76] 201		7777444
Li, H.2014	7	30	9	30	3.0%	0.71 [0.22, 2.25] 201		
Wen, H.2014	11	45	18	45	5.9%	0.49 [0.20, 1.20] 201		
Liu,Y.2014	8	43	9	43	3.2%	0.86 [0.30, 2.50] 201		
Zhu, H.2015	4	21	3	21	1.1%	1.41 [0.27, 7.26] 201	5	? ? ? ? + + 4
Zhang, M.2015	7	39	7	32	2.7%	0.78 [0.24, 2.52] 201	5	+ ? ? ? + + 4
Han, R.2015	3	36	5	36	2.0%	0.56 [0.12, 2.56] 201	5	+ ? ? ? + + 4
Li, X.2015	12	20	15	20	2.6%	0.50 [0.13, 1.93] 201	5	+ ? ? ? + + 4
Zhang, S.2016	1	19	1	19	0.4%	1.00 [0.06, 17.25] 201	6	?????
Ma, Y. 2016	2	33	8	35	3.2%	0.22 [0.04, 1.11] 201	3	<mark>? ? ? ? +</mark> + 4
Wu, Y.2017	10	109	32	109	12.6%	0.24 [0.11, 0.52] 201	· · · ·	• • ? ? • • •
Zhang, H.2017	2	52	7	52	2.9%	0.26 [0.05, 1.30] 201	· · · · · ·	🛨 ? ? ? 🕁 🛑 🤤
Ma, M.2017	9	42	13	42	4.4%	0.61 [0.23, 1.63] 201	· · · · ·	🕀 ? ? ? 🕀 🛑 🭕
Wu, T.2017	6	67	16	68	6.3%	0.32 [0.12, 0.88] 201	· · · · · ·	?????
Huang, W.2017	4	39	5	40	1.9%	0.80 [0.20, 3.23] 201		🕀 ? ? ? 🗣 🛑 🭕
Zhou, D.2018	4	58	8	58	3.2%	0.46 [0.13, 1.63] 201	3	?????
Su,D.2019	3	41	11	41	4.4%	0.22 [0.06, 0.84] 201	· · · · · · · · · · · · · · · · · · ·	?????++4
Geng,K.2020	16	45	13	45	3.6%	1.36 [0.56, 3.30] 202		• ? ? ? • • •
Guo, X.2020	5	51	7	51	2.7%	0.68 [0.20, 2.31] 202		• ? ? ? • • •
Chen,C.2020	9	49	10	49	3.5%	0.88 [0.32, 2.39] 202		????
Tan, H.2020	22	60	28	60	7.7%	0.66 [0.32, 1.37] 202		+ ? ? ? + + 4
Fotal (95% CI)		1284		1257	100.0%	0.58 [0.47, 0.72]	•	
Fotal events	192		285					
Heterogeneity: Chi ² = 2	20.28, df =	28 (P =	0.85); l ² = 0%					
Test for overall effect:							0.001 0.1 1 10	1000
		51000	,				Favours[Aidi injection] Favours[Gemcital	pine and cisplatin]

 Risk of bias legend.

 (A) Random sequence generation (selection bias)
 (B) Allocation concealment (selection bias)

 (B) Allocation concealment (selection bias)
 (C) Blinding of participants and personnel (performance bias)

 (D) Blinding of outcome assessment (detection bias)
 (E) Incomplete outcome data (attrition bias)

 (F) Selective reporting (reporting bias)
 (G) Other bias

Figure S30 The analysis of liver toxicity between the two groups

Study or Subgroup Wang,Y.2009	Events 0	Total	Events							
	0		Lyeins	Total	Weight	M-H, Fixed, 95% CI Yea	r	M-H, Fixed, 9	5% CI	ABCDEFG
14 0000		32	0	27		Not estimable 2009	9			????++?
Wen,K.2009	2	38	4	38	2.4%	0.47 [0.08, 2.75] 2009	9			????+++
Hong,Y.2010	4	90	7	70	4.7%	0.42 [0.12, 1.49] 2010)			????+++
Sun,J.2012	3	34	4	34	2.3%	0.73 [0.15, 3.52] 2012	2		-	
Wang, J.2012	4	25	4	24	2.1%	0.95 [0.21, 4.33] 2012	2		_	?????
Zhang,Y. 2012	5	41	6	42	3.2%	0.83 [0.23, 2.98] 2012	2			?????
Liu,Y.2014	8	43	9	43	4.6%	0.86 [0.30, 2.50] 2014	1			$\bullet ??? \bullet \bullet \bullet$
Wen, H.2014	4	45	6	45	3.4%	0.63 [0.17, 2.42] 2014	1			$\bullet ? ? ? \bullet \bullet \bullet$
Cheng, B.2014	3	49	6	52	3.4%	0.50 [0.12, 2.12] 2014	1			????
Li, H.2014	7	30	9	30	4.3%	0.71 [0.22, 2.25] 2014	1			?????
Li, X.2015	6	20	5	20	2.2%	1.29 [0.32, 5.17] 201	5			$\bullet ? ? ? \bullet \bullet \bullet$
Han, R.2015	3	36	5	36	2.9%	0.56 [0.12, 2.56] 201	5			$\bullet ? ? ? \bullet \bullet \bullet$
Zhu, H.2015	3	21	5	21	2.7%	0.53 [0.11, 2.59] 201				????+++
Zhang, M.2015	3	39	4	32	2.5%	0.58 [0.12, 2.82] 201	5			$\bullet ? ? ? \bullet \bullet \bullet$
Ma, Y. 2016	1	33	7	35	4.1%	0.13 [0.01, 1.08] 2016	3			????+++
Wu, Y.2017	13	109	30	109	16.5%	0.36 [0.17, 0.73] 201				$\bullet \bullet ? ? \bullet \bullet \bullet$
Ma, M.2017	9	42	13	42	6.4%	0.61 [0.23, 1.63] 2011		-+		• ? ? ? • • •
Huang, W.2017	4	39	5	40	2.8%	0.80 [0.20, 3.23] 201			-	• ? ? ? • • •
Zhou, D.2018	4	58	8	58	4.6%	0.46 [0.13, 1.63] 2018				????+++
Su.D.2019	1	41	4	41	2.4%	0.23 [0.02, 2.16] 2019				????+++
Geng,K.2020	16	45	13	45	5.2%	1.36 [0.56, 3.30] 2020			-	$\bullet ? ? ? \bullet \bullet \bullet$
Chen,C.2020	4	49	6	49	3.4%	0.64 [0.17, 2.41] 2020				????+++
Tan, H.2020	21	60	27	60	11.0%	0.66 [0.32, 1.37] 2020		-++		$\bullet ? ? ? \bullet \bullet \bullet$
Guo, X.2020	4	51	5	51	2.9%	0.78 [0.20, 3.10] 2020			-	• ? ? ? • • •
Total (95% CI)		1070		1044	100.0%	0.62 [0.48, 0.79]		•		
Total events	132		192							
Heterogeneity: Chi ² =		22 (P =					H			
Test for overall effect:							0.001		10 1000	
	V							Favours[Aidi injection] Fav	ours[Gemcitabine and cispl	aunj

 Risk of bias legend.

 (A) Random sequence generation (selection bias)
 (B) Allocation concealment (selection bias)

 (C) Blinding of participants and personnel (performance bias)
 (D) Blinding of outcome assessment (detection bias)

 (E) Incomplete outcome data (attrition bias)
 (F) Selective reporting (reporting bias)

 (G) Other bias
 (E) Selective reporting (reporting bias)

Figure S31 The analysis of renal toxicity between the two groups

	Aidi inje	ction	Gemcitabine and cispl	latin		Odds Ratio	Odds Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl	ABCDEFG
Liu,Y.2010	15	32	29	32	35.3%	0.09 [0.02, 0.36]		?????+++
Song,Z.2009	4	30	3	30	32.5%	1.38 [0.28, 6.80]		????? 🔁 🖶 🕀
Wang,Y.2009	22	32	25	27	32.1%	0.18 [0.03, 0.89]		????++?
Total (95% CI)		94		89	100.0%	0.27 [0.05, 1.37]		
Total events	41		57					
Heterogeneity: Tau ² =	1.42; Chi2	= 6.69, 0	df = 2 (P = 0.04); I ² = 70%	5				
Test for overall effect:	Z = 1.58 (F	9 = 0.11)					0.01 0.1 1 10 Favours[Aidi injection] Favours[Gemcitabine	100 and cisplatin]

<u>Risk of bias legend</u> (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)

(G) Other bias

Figure S32 The analysis of alopecia between the two groups




Figure S33 The analysis of neurotoxicity between the two groups




Figure S34 The analysis of oral mucositis between the two groups